Effects of Dydrogesterone combined with Estradiol valerate in treatment of patients with perimenopausal dysfunctional uterine bleeding
Objective:To observe effects of Dydrogesterone combined with Estradiol valerate in treatment of patients with perimenopausal dysfunctional uterine bleeding(DUB).Methods:The clinical data of 80 patients with perimenopausal DUB admitted to this hospital from March 2021 to January 2023 were retrospectively analyzed.According to different treatment options,they were divided into control group and study group,40 cases in each group.The control group was treated with Estradiol valerate tablets,while the study group was treated with Dydrogesterone tablets on the basis of that of the control group.The clinical efficacy,the endometrial thickness before and after the treatment,the hemostatic effect,the levels of hemoglobin(Hb)and sex hormones[progesterone(P),estradiol(E2),luteinizing hormone(LH),follicle stimulating hormone(FSH)]before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the study group was 92.50%(37/40),which was higher than 75.00%(30/40)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the endometrial thickness levels of the two groups were smaller than those before the treatment,that of the study group was smaller than that of the control group,and the differences were statistically significant(P<0.05).After the treatment,the Hb levels of the two groups were higher than those before the treatment,that of the study group was higher than that of the control group,and the differences were statistically significant(P<0.05).The bleeding control time and the complete hemostasis time of the study group were shorter than those of the control group,and the differences were statistically significant(P<0.05).The levels of E2,FSH,LH and P in the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Dydrogesterone combined with Estradiol valerate in the treatment of the perimenopausal DUB patients can improve the total effective rate of treatment and the Hb levels,shorten the bleeding control time and the complete hemostasis time,and reduce the endometrial thickness and the sex hormone levels.Moreover,it is superior to single Estradiol valerate treatment.
万方数据
维普
